Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMANUEL JEAN-MARIE MIGNOT

Allopathic & Osteopathic Physicians Psychiatry & Neurology Sleep Medicine

NPI
1023151800
CMS profile
961917
Location
STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$47,971.34

26 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $27,549.24 14
Avadel CNS Pharmaceuticals, LLC $11,180.09 3
Alkermes, Inc. $4,743.27 5
Eisai Inc. $3,000.00 1
SANOFI US SERVICES INC. $1,324.00 1
JAZZ PHARMACEUTICALS INC. $137.65 1
Axsome Therapeutics, Inc. $37.09 1

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMANUEL JEAN-MARIE MIGNOT

NPI 1023151800 · CMS profile ID 961917

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Sleep Medicine

STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
EMMANUEL JEAN-MARIE MIGNOT, NPI 1023151800, CMS profile ID 961917, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1023151800?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

26 matching records · $47,971.34 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 26 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–26 of 26.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alkermes, Inc. $1,675.0011/24/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1222569494 CMS
Takeda Pharmaceuticals U.S.A., Inc. $89.6611/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223943301 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,500.0011/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223787615 CMS
Alkermes, Inc. $1,340.0010/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223443584 CMS
Alkermes, Inc. $1,650.0010/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223443582 CMS
Alkermes, Inc. $19.1609/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222569486 CMS
Alkermes, Inc. $59.1109/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222569488 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.8409/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223942679 CMS
Takeda Pharmaceuticals U.S.A., Inc. $73.1208/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223943095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $78.2008/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223944438 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,300.0007/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223793635 CMS
SANOFI US SERVICES INC. $1,324.0007/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1233456988 CMS
Axsome Therapeutics, Inc. $37.0906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235300749 CMS
JAZZ PHARMACEUTICALS INC. $137.6506/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234305277 CMS
Takeda Pharmaceuticals U.S.A., Inc. $86.9306/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223944464 CMS
Eisai Inc. $3,000.0006/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244478304 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.2105/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223941865 CMS
Takeda Pharmaceuticals U.S.A., Inc. $106.6605/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223943339 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,000.0005/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223792304 CMS
Takeda Pharmaceuticals U.S.A., Inc. $65.6203/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223944370 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10,422.0002/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1223795110 CMS
Avadel CNS Pharmaceuticals, LLC $39.2801/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208538514 CMS
Avadel CNS Pharmaceuticals, LLC $3,815.0001/15/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1208538510 CMS
Avadel CNS Pharmaceuticals, LLC $7,325.8101/15/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1208538512 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,895.0001/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223793497 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,895.0001/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1223793499 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,292.12 9
PY2020 $14,160.00 5
PY2021 $23,131.44 17
PY2022 $2,844.54 7
PY2023 $4,565.65 9
PY2024 $40,598.94 22
PY2025 $47,971.34 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $992.00 1
PY2025 Principal investigator $2,401,878.07 533
PY2024 Principal investigator $1,022,037.24 254
PY2023 Principal investigator $275,388.22 59
PY2022 Principal investigator $175,960.37 12
PY2021 Principal investigator $361,355.25 19
PY2020 Recipient $3,276.62 36
PY2020 Principal investigator $214,065.50 29
PY2019 Recipient $921.37 2
PY2019 Principal investigator $67,788.78 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,294.37 12/31/2023 Non-covered Recipient Entity
Stanford University
Clinical Trial to Characterize Symptoms of Excessive Daytime Sleepiness Following Treatment Withdrawal in Participants with Narcolepsy Type 1 No dispute reported 06/30/2026 1042490883
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $18,125.00 12/15/2023 Covered Recipient Teaching Hospital
BOARD OF TRUSTEES OF THE UNIVERSITY
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) No dispute reported 06/30/2026 1039783737
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,584.00 12/15/2023 Covered Recipient Teaching Hospital
BOARD OF TRUSTEES OF THE UNIVERSITY
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) No dispute reported 06/30/2026 1039783801
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,560.00 12/15/2023 Covered Recipient Teaching Hospital
BOARD OF TRUSTEES OF THE UNIVERSITY
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) No dispute reported 06/30/2026 1039783867
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,477.00 12/15/2023 Covered Recipient Teaching Hospital
BOARD OF TRUSTEES OF THE UNIVERSITY
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) No dispute reported 06/30/2026 1039783927
Principal investigator 1 Eisai Inc. $7,680.00 11/14/2023 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1025459503
Principal investigator 1 Vanda Pharmaceuticals Inc. $6,784.00 11/08/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) No dispute reported 06/30/2026 1051532643
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $14.70 11/07/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059685339
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $7.84 11/07/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059686201
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $53,373.74 11/01/2023 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) No dispute reported 06/30/2026 1039783671
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,160.60 09/26/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039762241
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,160.60 09/26/2023 Covered Recipient Teaching Hospital
STANFORD HEALTH CARE
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039805985
Principal investigator 1 Eisai Inc. $19,895.06 07/28/2023 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1025459485
Principal investigator 1 Eisai Inc. $11,696.69 07/28/2023 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Lemborexant in Delayed Sleep Phase Syndrome No dispute reported 06/30/2026 1025459491
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,155.26 06/02/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059681145
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4,046.08 03/20/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678407
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,280.00 03/20/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678451
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,199.04 03/20/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678457
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,154.24 03/20/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678463
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $455.00 03/03/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678365
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,161.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039848977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,576.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039848995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,536.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039849011
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,600.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039849029
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,250.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039849045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $378.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039849061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,857.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039849075
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $93.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039849127
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,787.00 03/03/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039849141
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,584.00 02/23/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039848055
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,280.00 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678229
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $64.00 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678235
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,317.12 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678241
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,600.00 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678247
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,920.00 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678253
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $718.08 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678259
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,920.00 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678265
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $359.04 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678273
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $192.00 02/22/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678279
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,200.00 02/22/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
TAK-994-1504 Open Label Extension No dispute reported 06/30/2026 1039847805
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,920.00 02/08/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678125
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,584.00 02/08/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678131
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,200.00 02/08/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678137
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,840.00 02/08/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678143
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,400.00 02/08/2023 Non-covered Recipient Entity
LUCILE PACKARD CHILDREN'S HOSPITAL STANFORD UNIVERSITY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059678149
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $309.00 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679039
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $164.80 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679045
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9.00 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679757
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.00 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679763
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $4.80 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059679777
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $55.96 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680057
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $38.80 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680313
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18.00 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680735
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6.30 02/06/2023 Non-covered Recipient Entity
ORLANDO HEALTH PEDIATRIC NEUROLOGY
A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY No dispute reported 06/30/2026 1059680741
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,340.00 02/06/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) No dispute reported 06/30/2026 1051527705
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,161.00 01/06/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1039840787
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,600.00 01/06/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1039840807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,200.00 01/06/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1039840827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $45,035.10 01/04/2023 Non-covered Recipient Entity
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE RISING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-994 IN PATIENTS WITH NARCOLEPSY WITH OR WITHOUT CATAPLEXY (NARCOLEPSY TYPE 1 OR NARCOLEPSY TYPE 2) No dispute reported 06/30/2026 1039840287